Credence

FDA Adopts ‘Super Intelligence’ Terminology as Agency Expands Focus on Emerging Technology


Key Points

  • FDA will use "Super Intelligence" (SI) instead of artificial intelligence in new public-facing communications starting November 16, 2026, per Executive Order 14434.
  • The terminology change does not alter submission requirements, regulations, or product names for sponsors, manufacturers, or other regulated entities.
  • FDA launched an online SI resource hub as it expands focus on advanced computational technologies in drug, biologic, and device development.

The U.S. Food and Drug Administration (FDA) is changing how it refers to artificial intelligence (AI), adopting the term “Super Intelligence” (SI) in new public-facing communications beginning November 16, 2026. The terminology change follows a September 29 executive order issued by President Donald Trump, directing federal agencies to replace references to artificial intelligence with Super Intelligence in official communications, reports, websites, policy documents, and other non-statutory materials.

Executive Order 14434, titled Inaugurating the Era of Super Intelligence, defines SI as encompassing the technologies and systems already covered under the federal statutory definition of artificial intelligence. The directive applies to executive branch agencies and does not establish new regulatory requirements for companies submitting information to the FDA.

Under the change, the FDA will incorporate the revised terminology into newly issued public-facing materials where applicable and legally permissible. Existing regulations, guidance documents, Federal Register notices, and other previously published materials will remain in effect as written until they undergo substantive revision or routine website maintenance. The agency will also continue using the original AI terminology when quoting or referencing statutes and regulations that specifically use those terms.

The FDA emphasized that the executive order does not change existing submission requirements for sponsors, applicants, manufacturers, or other regulated entities. Companies will not need to revise established or proprietary product names, trade names, labeling, or other submission materials solely to reflect the terminology shift. Agency forms, electronic submission templates, databases, and website content will be updated through their normal maintenance processes.

The terminology change comes as the FDA increases its attention to the growing role of advanced computational technologies across the industries it regulates. According to the agency, SI applications are gaining traction in drug and biologic development, medical device innovation, food safety monitoring, and other areas with implications for public health.

The FDA has identified supporting the responsible development of these technologies as an important part of its public health mission. Its approach centers on encouraging innovation while promoting the safety, effectiveness, and quality of products developed with SI-based tools. The agency also points to the need for greater consistency and predictability in how these technologies are developed and evaluated as part of the regulatory process.

To help industry stakeholders navigate the evolving landscape, the FDA has established an online SI resource hub. The site brings together agency information and resources for manufacturers, researchers, healthcare professionals, and the public, including details about how the FDA is incorporating SI into its own operations and its broader efforts to support innovation.

The agency’s work in this area is part of its broader Strategic Pillars for Innovation and Global Leadership, which identify technological advancement and regulatory modernization as priorities.

For pharmaceutical and biotechnology companies, the terminology update is largely administrative rather than a change in regulatory policy. However, the FDA’s broader focus on the application of SI in product research, development, and review underscores the growing importance of these technologies across the life sciences sector. As adoption expands, industry will be watching for further agency guidance on how SI-enabled tools can be incorporated into regulated development programs while maintaining established standards for product quality, safety, and effectiveness.

Learn more at www.fda.gov.